PWM
BCRX icon

Perigon Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Perigon Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-87
Closed – – 270
2018
Q1 		$0 Buy
+87
New +$447 ﹤0.01% 640

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Perigon Wealth Management's BCRX Position: Q2 2018 in Review

Perigon Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2018, closing a stake of 87 shares.

Perigon Wealth Management first reported a position in BCRX in Q1 2018 and held it in 1 quarter. The position peaked at $0 in Q1 2018. 103 funds tracked by Wall St. Rank hold BCRX as of Q2 2018.

  • Perigon Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Perigon Wealth Management sold 87 BioCryst Pharmaceuticals shares in Q2 2018.
  • Perigon Wealth Management first reported a position in BioCryst Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Perigon Wealth Management's BioCryst Pharmaceuticals position peaked at $0 in Q1 2018.
  • 103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2018.

Based on Perigon Wealth Management's 13F filing for Q2 2018, filed 7 Aug 2018.